<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04124913</url>
  </required_header>
  <id_info>
    <org_study_id>2019/001</org_study_id>
    <nct_id>NCT04124913</nct_id>
  </id_info>
  <brief_title>Oral Dydrogesterone vs. Micronized Vaginal Progesterone for Luteal Phase Support in Frozen-thawed Embryo Transfer Cycles</brief_title>
  <official_title>Comparison of Oral Dydrogesterone Versus Micronized Vaginal Progesterone for Luteal Phase Support in Frozen-thawed Embryo Transfer Cycles: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sisli Hospital, Istanbul</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sisli Hospital, Istanbul</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this randomized controlled trial is to compare the efficacy of oral dydrogesterone
      vs. micronized vaginal progesterone for luteal phase support in frozen-thawed embryo transfer
      cycles.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2, 2019</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ongoing pregnancy rate</measure>
    <time_frame>12 weeks after the last menstrual period of the patient</time_frame>
    <description>Presence of at least one live fetus at the end of the 12th gestational week</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical pregnancy rate</measure>
    <time_frame>6-7 weeks after the last menstrual period of the patient</time_frame>
    <description>Presence of an intrauterine gestational sac with fetal heart beat at 7th week of gestation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implantation rate</measure>
    <time_frame>5 weeks after the last menstrual period of the patient</time_frame>
    <description>Percentage of gestational sacs compared to the number of embryos transferred</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical pregnancy</measure>
    <time_frame>10 days after embryo transfer</time_frame>
    <description>Positive serum beta HCG test performed 10 days after embryo transfer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical miscarriage</measure>
    <time_frame>before 5th gestational week</time_frame>
    <description>pregnancy loss before ultrasonographic detection of an intrauterine gestational sac</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical miscarriage</measure>
    <time_frame>after 5th gestational week</time_frame>
    <description>pregnancy loss after ultrasonographic detection of an intrauterine gestational sac</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>headache rate</measure>
    <time_frame>6-7 weeks after the last menstrual period of the patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>interference with coitus rate</measure>
    <time_frame>6-7 weeks after the last menstrual period of the patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>somnolence rate</measure>
    <time_frame>6-7 weeks after the last menstrual period of the patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>dizziness rate</measure>
    <time_frame>6-7 weeks after the last menstrual period of the patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>nausea/vomiting rate</measure>
    <time_frame>6-7 weeks after the last menstrual period of the patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>vaginal discharge rate</measure>
    <time_frame>6-7 weeks after the last menstrual period of the patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>perineal irritation rate</measure>
    <time_frame>6-7 weeks after the last menstrual period of the patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>abdominal pain rate</measure>
    <time_frame>6-7 weeks after the last menstrual period of the patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mastalgia rate</measure>
    <time_frame>6-7 weeks after the last menstrual period of the patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>vaginal bleeding rate</measure>
    <time_frame>6-7 weeks after the last menstrual period of the patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>interference with intercourse rate</measure>
    <time_frame>6-7 weeks after the last menstrual period of the patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall satisfaction score</measure>
    <time_frame>6-7 weeks after the last menstrual period of the patient</time_frame>
    <description>patient satisfaction from the drug used measured on a 1-5 scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Infertility, Female</condition>
  <condition>Infertility, Male</condition>
  <condition>Embryo Transfer</condition>
  <condition>Fertilization in Vitro</condition>
  <condition>Drug Effect</condition>
  <condition>Reproductive Techniques, Assisted</condition>
  <condition>Progesterone</condition>
  <condition>Dydrogesterone</condition>
  <arm_group>
    <arm_group_label>Dydrogesterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaginal progesterone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dydrogesterone 10 MG Oral Tablet</intervention_name>
    <description>Oral dydrogesterone 10 mg tablet three times a day for luteal phase support</description>
    <arm_group_label>Dydrogesterone</arm_group_label>
    <other_name>Duphaston</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone Vaginal Gel [Crinone]</intervention_name>
    <description>Vaginal progesterone gel 90 mg once a day for luteal phase support</description>
    <arm_group_label>Vaginal progesterone</arm_group_label>
    <other_name>Crinone %8 vaginal progesterone gel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ages between 20 and 40

          -  Modified natural frozen- thawed embryo transfer cycles

        Exclusion Criteria:

          -  Recurrent implantation failure

          -  Recurrent pregnancy loss

          -  Presence of uterine pathology
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Semra Kahraman, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Şişli Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gonul Ozer, MD</last_name>
    <phone>+905326945549</phone>
    <email>drgonulozer@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kadriye B Yuksel, MD</last_name>
    <phone>+905438852666</phone>
    <email>berilyuksel@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Şişli Hospital</name>
      <address>
        <city>Istanbul</city>
        <state>Şişli</state>
        <zip>34385</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gonul Ozer, MD</last_name>
      <phone>+905326945549</phone>
      <email>drgonulozer@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Kadriye B Yuksel, Assoc. Prof.</last_name>
      <phone>+905438852666</phone>
      <email>berilyuksel@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Semra Kahraman, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gonul Ozer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kadriye B Yüksel, Assoc. Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ozge S Yucel Cicek, Asst. Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 10, 2019</study_first_submitted>
  <study_first_submitted_qc>October 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2019</study_first_posted>
  <last_update_submitted>October 10, 2019</last_update_submitted>
  <last_update_submitted_qc>October 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Memorial Sisli Hospital, Istanbul</investigator_affiliation>
    <investigator_full_name>Gönül Özer</investigator_full_name>
    <investigator_title>Medical doctor</investigator_title>
  </responsible_party>
  <keyword>oral dydrogesterone</keyword>
  <keyword>luteal phase support</keyword>
  <keyword>vaginal progesterone gel</keyword>
  <keyword>frozen-thawed embryo transfer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
    <mesh_term>Infertility, Male</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
    <mesh_term>Dydrogesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

